The role of interleukin 17 in Crohn's disease-associated intestinal fibrosis

Conclusions: Our results suggest that IL-17A, but not IL-17E, is pro-fibrotic in CD. Further studies are needed to clarify whether the therapeutic blockade of IL-17A through the anti-IL-17A monoclonal antibody secukinumab is able to counteract the fibrogenic process in CD.
Source: Fibrogenesis and Tissue Repair - Category: Biomedical Science Authors: Source Type: research